<!DOCTYPE html><!-- Last Published: Tue Jan 07 2025 15:55:23 GMT+0000 (Coordinated Universal Time) --><html data-wf-domain="www.cambrianbio.com" data-wf-page="65e8fe9201c0e422942549c6" data-wf-site="600be113c4111047016de64a" lang="en"><head><meta charset="utf-8"/><title>News and Publications</title><meta content="Learn the latest from cambrian Bio" name="description"/><meta content="News and Publications" property="og:title"/><meta content="Learn the latest from cambrian Bio" property="og:description"/><meta content="News and Publications" property="twitter:title"/><meta content="Learn the latest from cambrian Bio" property="twitter:description"/><meta property="og:type" content="website"/><meta content="summary_large_image" name="twitter:card"/><meta content="width=device-width, initial-scale=1" name="viewport"/><link href="https://cdn.prod.website-files.com/600be113c4111047016de64a/css/cambrian-dev.webflow.0733b0f40.min.css" rel="stylesheet" type="text/css"/><script type="text/javascript">!function(o,c){var n=c.documentElement,t=" w-mod-";n.className+=t+"js",("ontouchstart"in o||o.DocumentTouch&&c instanceof DocumentTouch)&&(n.className+=t+"touch")}(window,document);</script><link href="https://i0.wp.com/www.kibs.co.ke/wp/wp-content/uploads/2023/10/kibs-logo-02.png?fit=120,85&amp;ssl=1" rel="shortcut icon" type="image/x-icon"/><link href="https://cdn.prod.website-files.com/600be113c4111047016de64a/600be12d2137ed834d86305c_webclip.png" rel="apple-touch-icon"/><script async="" src="https://www.googletagmanager.com/gtag/js?id=G-Y7NNGFHMFL"></script><script type="text/javascript">window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}gtag('js', new Date());gtag('config', 'G-Y7NNGFHMFL', {'anonymize_ip': false});</script><meta name="pinterest" content="nopin" />
<meta name="twitter:card" content="summary_large_image">

<!-- CUSTOM STYLE -->
<style>
html{-webkit-font-smoothing:antialiased;-moz-font-smoothing:antialiased;-o-font-smoothing:antialiased}
body{overscroll-behavior:none;-webkit-tap-highlight-color:transparent}
input,select,textarea{appearance:none;-moz-appearance:none;-webkit-appearance:none}
  
@media screen and (max-width:767px){
  .modal{display:block}
  .modal .c-660{height:-webkit-fill-available}
  .modal .abs-shadow-card{display:none}
  .modal h3{font-size:1.75em}
  }
</style>
<!-- END CUSTOM STYLE -->

<style>
.s.nav,.menu{background-color:#F8F0E5;color:#0D141F}
.menu-bar{background-color:#0D141F}
.footer .s:first-child{background:linear-gradient(360deg, #081B42 0%, #592A2A 100%)}
.footer .s:last-child{background-color:#081B42}
</style></head><body class="body-linen"><div class="no w-embed"><style>
a{color:inherit}
.notif-wrap ~ .nav{position:relative!important;transform:none!important}
.nav-wrap.with-notif{transform:none!important}
input:valid{border-color:#36c}
.w-form-done p{font-weight:500!important}
.w-form-fail{padding:1em;border-radius:10px;font-size:1em;text-align:center;margin-top:1em;font-weight:400;letter-spacing:-0.02em}
.row:first-child,.row-team:first-child,.pipeline .w-dyn-item:first-child .grid,.rt.preview p:first-child{margin-top:0}
.link-social:last-child{margin-right:0}
.tr{pointer-events:none}
.btn:not(.btn-blue):not(.btn-maroon):not(.btn-upload){background:linear-gradient(90deg, #109E5A 0%, #3366CC 100%)}
.abs svg{position:absolute;left:0;top:0;right:0;bottom:0;width:100%;height:auto}
.abs.abs-bg-bot svg{top:auto}
.abs.abs-footer svg,.c-404 svg{height:100%}
.s-404{max-height:-webkit-fill-available}
.cta p{display:inline-block;font-weight:500;line-height:1.4}
.cta:hover .cta-arrow,.cta:focus .cta-arrow,.link-block:hover .cta-arrow,.link-block:focus .cta-arrow{transform:translateX(.25em)}
.cta:hover .cta-arrow.cta-arrow-inverse,.cta:focus .cta-arrow.cta-arrow-inverse{transform:translateX(-.25em)}
.clamp{overflow:hidden;display:-webkit-box;-webkit-box-orient:vertical;-webkit-line-clamp:3}
.clamp.clamp2{-webkit-line-clamp:2}
.item::after{content:"";background:radial-gradient(circle at 50%,#d8a76e,#f8f0e5);display:block;position:absolute;bottom:0;width:100%;height:1px}
.link-block .cta{transition:opacity 500ms}
.link-block:hover .cta,.link-block:focus .cta,.link-external:hover ~ a .cta,.link-external:focus ~ a .cta{opacity:60%}
.rt blockquote + h6{color:#fff;position:relative;bottom:7em;margin-bottom:-1em}
.rt blockquote + h6 em{font-weight:300;color:#D8A76E;margin-left:1.4em}
.rt figure,.rt .w-embed{margin:3.75em 0}
.rt figure:last-child,.rt .w-embed:last-child{margin-bottom:0}
.rt figure, .rt .w-embed{border-radius:.938em;-webkit-mask-image:-webkit-radial-gradient(white, black)}
.rt figure.w-richtext-figure-type-image,.article img{border-radius:.625em}
.s-privacy .rt a{color:#b1c3e8}
.bg{transform:scale3d(1,1,1);transform-style:preserve-3d}
.link-qa:hover .bg,.link-qa:focus .bg,.link-external:hover ~ .link-qa .bg,.link-external:focus ~ .link-qa .bg{transform:scale3d(1.025,1.025,1)}
.link-qa:hover .btn,.link-qa:focus .btn{filter:brightness(120%);-webkit-filter:brightness(120%)}
.featured .w-dyn-list, .featured .w-dyn-items,.featured .w-dyn-item,.featured .link-qa{height:100%}
.w-file-upload-default,.w-file-upload-uploading{height:3.176470588235294em;display:block}
.w-file-upload-file-name{font-size:inherit}

@media screen and (max-width:479px){
.link-footer:not(:first-child){margin-right:0}
.rt blockquote + h6,.rt blockquote + h6 em{margin-left:0!important}
.rt blockquote + h6{bottom:6em!important;margin-bottom:-3em!important}
.rt blockquote + h6 em{display:block}
.link-qa img{transform:none!important}
.link-qa{color:#F8F0E5!important}
.s1-home,.s1-about,.s1-pipeline,.s1-science{max-height:none!important}
.s1.s1-team{max-height:-webkit-fill-available!important}
.link-contact .btn{width:100%;text-align:center}
.s1{max-height:-webkit-fill-available}
}
@media screen and (min-width:480px){.abs-qa{background-color:transparent!important}}
@media screen and (max-width:767px){
.rt figure,.rt .w-embed{margin:2.5em 0}
.link-team h3{font-size:1.5em}
.rt h2:first-child{margin-top:1.5em}
.card-modal{min-height:-webkit-fill-available}
}
@media screen and (min-width:768px) and (max-width:991px){.s1{max-height:-webkit-fill-available}}
@media screen and (max-width:991px){
.rt blockquote + h6{margin-left:60px;bottom:4.5em;margin-bottom:-1.5em}
.rt blockquote + h6 em{margin-left:1em}
.item .pc.pc-4{margin-top:.2em}
}
@media screen and (min-width:992px){
.s.s1:not(.s1-team){height:calc(100vh + 1vw)}
.s.s1.s1-about{height:calc(100vh + 5vw)}
.s.s1.s1-science{height:calc(100vh + 2vw)}
.row-team:nth-child(3) .grid{-ms-grid-columns:1fr 1fr 1fr 1fr;grid-template-columns:1fr 1fr 1fr 1fr}
.row-team:nth-child(3) h3{font-size:1.25em;font-weight:500}
.menu{background:none!important}
.grid-qa-2 .w-dyn-item:first-child{display:none}
}
@media screen and (min-width:992px) and (max-width:1180px){
.rt blockquote + h6{left:2.75em}
.rt blockquote{margin-left:-1.5em;margin-right:-1.5em}
.c1-contact{padding-top:30px}
.left-110{padding-left:0}
.right-110{padding-right:0}
.c2-contact .left-110{padding-left:3em}
.c2-contact .right-110{padding-right:3em}
.grid.grid-pipeline{font-size:1.2vw}
}
@media screen and (min-width:992px) and (max-width:1360px){body{font-size:14px}}
@media screen and (min-width:992px) and (max-width:1360px){.p-17.p-pipeline-phase.categ{font-size:16px}}
@media screen and (min-width:1792px){
.grid.grid-gap-143{grid-column-gap:8.9375em}
.left-110{padding-left:6.875em}
.right-110{padding-right:6.875em}
}
@media screen and (min-width:2200px){body{font-size:18px}}
</style></div><div class="tr" data-ix="tr"></div><div data-collapse="medium" data-animation="default" data-duration="800" data-easing="ease-out-expo" data-easing2="ease-out-expo" data-w-id="710a0016-3feb-10ed-f3e7-f258a52639cb" role="banner" class="s nav w-nav"><nav class="c"><div class="logo"><a href="index.html" aria-label="home" class="w-inline-block"><div class="w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="7.1875em" height="1.25em" viewBox="0 0 115 20" fill="currentColor"><path d="M104.144 7.712a5.74 5.74 0 0 1 3.918-1.489 6.14 6.14 0 0 1 2.638.589c.823.389 1.543.956 2.107 1.657.836 1.029 1.28 2.327 1.28 4.518v6.226h-2.641v-6.377c0-1.626-.304-2.382-.776-2.951a3.44 3.44 0 0 0-1.199-.91c-.464-.213-.971-.322-1.484-.32a4.92 4.92 0 0 0-2.083.495 4.79 4.79 0 0 0-1.657 1.327v8.736h-2.641V6.496h2.557l-.019 1.216zM36.15 6.559V7.78c1.04-.948 2.409-1.48 3.833-1.489.881-.005 1.752.182 2.549.547s1.501.898 2.06 1.562a6.54 6.54 0 0 1 2.246-1.577c.855-.364 1.781-.545 2.714-.532a6.04 6.04 0 0 1 2.569.552 5.89 5.89 0 0 1 2.068 1.584c.804.975 1.192 2.218 1.192 4.359v6.49h-2.637V12.38c0-1.303-.276-2.004-.748-2.546a3.2 3.2 0 0 0-1.098-.815c-.423-.191-.882-.291-1.347-.291a5.49 5.49 0 0 0-2.187.497 5.36 5.36 0 0 0-1.787 1.325 10.14 10.14 0 0 1 .234 2.236v6.49h-2.637V12.38c0-1.303-.28-2.004-.753-2.546-.315-.35-.703-.63-1.139-.821s-.908-.288-1.386-.286c-.709.03-1.403.209-2.035.523s-1.188.757-1.63 1.299v8.727H33.59V6.559h2.557zM9.817.001c1.33-.014 2.648.238 3.874.741a9.71 9.71 0 0 1 3.25 2.183L15.754 4.1a.95.95 0 0 1-1.225.082C13.187 3.147 11.528 2.58 9.817 2.57c-3.974 0-7.054 3.088-7.054 7.169 0 4.277 3.165 7.174 7.302 7.174 1.891-.034 3.697-.774 5.044-2.068a.95.95 0 0 1 1.257 0l1.253 1.116c-.915 1.092-2.067 1.974-3.373 2.582a10.03 10.03 0 0 1-4.181.934C4.277 19.481 0 15.341 0 9.739 0 4.277 4.207.001 9.817.001zm69.715 7.87a.85.85 0 0 1-.069.335.87.87 0 0 1-.196.283c-.084.081-.183.145-.293.188s-.227.065-.345.064a4.62 4.62 0 0 0-2.202.582 4.47 4.47 0 0 0-1.631 1.554v8.335h-2.641V6.496h2.557v1.512a4.9 4.9 0 0 1 1.774-1.254 5.02 5.02 0 0 1 2.158-.376c.297-.002.594.016.888.055v1.439zM82.421.269a1.79 1.79 0 0 1 .672.129 1.75 1.75 0 0 1 .569.37 1.7 1.7 0 0 1 .38.555 1.66 1.66 0 0 1 .132.654 1.64 1.64 0 0 1-.137.646 1.68 1.68 0 0 1-.382.545 1.73 1.73 0 0 1-.568.359 1.76 1.76 0 0 1-.666.117 1.73 1.73 0 0 1-.663-.12 1.69 1.69 0 0 1-.562-.363 1.66 1.66 0 0 1-.372-.548 1.61 1.61 0 0 1-.123-.646 1.64 1.64 0 0 1 .124-.648c.085-.206.211-.393.371-.552a1.7 1.7 0 0 1 .561-.369 1.76 1.76 0 0 1 .664-.13zm-1.304 6.226h2.641v12.717h-2.641V6.496zm-52.512.001v8.736a4.49 4.49 0 0 1-1.57 1.322c-.621.316-1.31.487-2.011.5-.569.01-1.134-.092-1.663-.298a4.27 4.27 0 0 1-1.412-.905c-.404-.391-.724-.856-.94-1.369s-.325-1.063-.319-1.618c0-2.218 1.58-4.195 3.702-4.195a3.19 3.19 0 0 1 1.575.355.96.96 0 0 0 .584.11c.202-.026.389-.116.534-.255l1.402-1.366a6.24 6.24 0 0 0-3.885-1.284c-1.12-.013-2.222.267-3.193.811-1.031.602-1.883 1.456-2.471 2.476s-.894 2.174-.885 3.344c-.013 1.164.287 2.311.872 3.327a6.74 6.74 0 0 0 2.457 2.462 6.82 6.82 0 0 0 3.272.838 6.09 6.09 0 0 0 4.03-1.435v1.166h2.552V6.496h-2.632zm67.461-.119V15.1c-.412.553-.949 1.005-1.571 1.321a4.63 4.63 0 0 1-2.01.501 4.36 4.36 0 0 1-1.663-.3 4.27 4.27 0 0 1-1.412-.906 4.15 4.15 0 0 1-.939-1.37 4.06 4.06 0 0 1-.319-1.618c0-2.218 1.585-4.195 3.707-4.195.546-.017 1.088.106 1.571.355a.96.96 0 0 0 .584.11c.202-.026.389-.116.534-.255l1.402-1.366c-1.005-.74-2.211-1.178-3.469-1.259a6.6 6.6 0 0 0-3.609.803 6.79 6.79 0 0 0-2.474 2.473c-.589 1.021-.895 2.173-.887 3.344a6.51 6.51 0 0 0 .872 3.329c.585 1.016 1.434 1.864 2.461 2.46a6.81 6.81 0 0 0 3.272.838c1.477.022 2.911-.489 4.025-1.435v1.166h2.552V6.377h-2.627zm-28.978.656c-.971-.544-2.073-.824-3.193-.811a6.15 6.15 0 0 0-3.922 1.366l1.309 1.339a.94.94 0 0 0 .53.274.96.96 0 0 0 .592-.096 3.34 3.34 0 0 1 1.543-.373c2.211 0 3.861 1.904 3.861 4.099.006.554-.103 1.104-.319 1.616s-.535.978-.938 1.369a4.27 4.27 0 0 1-1.411.905 4.36 4.36 0 0 1-1.661.3c-.702-.012-1.391-.182-2.014-.498a4.49 4.49 0 0 1-1.572-1.323V0h-2.636v19.212h2.58v-1.166c1.113.947 2.547 1.458 4.025 1.435a6.83 6.83 0 0 0 3.272-.838c1.027-.596 1.875-1.445 2.46-2.461a6.52 6.52 0 0 0 .873-3.328c.007-1.173-.301-2.328-.894-3.349a6.81 6.81 0 0 0-2.486-2.472z"/></svg></div></a></div><nav role="navigation" id="menu" class="menu w-nav-menu"><div class="menu-inner"><div class="no-tb"></div><div class="center"><a href="about.html" tabindex="0" class="navlink">About</a><a href="science.html" tabindex="0" class="navlink">Science</a><a href="pipeline.html" class="navlink">Pipeline</a><a href="team.html" class="navlink">Team</a><a href="careers-page.html" class="navlink">Careers</a><a href="news-and-publications.html" aria-current="page" class="navlink w--current">News &amp; Publications</a><a href="blogs.html" class="navlink">Blog</a></div><div class="right"><a role="button" href="contact.html" target="_blank" class="btn btn-sm w-button">Contact</a></div></div></nav><div class="menu-btn w-nav-button"><div class="menu-bar menu-bar-top"></div><div class="menu-bar menu-bar-mid"></div><div class="menu-bar menu-bar-bot"></div></div></nav></div><main class="main"><section class="s"></section><section class="s s-newspublications"><div class="c"><div class="flex-center justify-space-between"><h1 class="h1-h2 news-and-pub">News &amp; Publications</h1></div><div class="margin-4-top"><div class="w-dyn-list"><div role="list" class="grid-3-col w-dyn-items"><div role="listitem" class="collection-item w-dyn-item"><a style="background-color:#68a3a7" href="news-and-publications/press-release-cambrian-bio-named-an-honoree-of-fast-companys-next-big-things-in-tech-award.html" class="news-card w-inline-block"><div class="text-white"><div class="margin-1-bottom"><h3>Press Release: cambrian Bio Named an Honoree of Fast Company&#x27;s Next Big Things in Tech Award</h3></div><div class="flex-center"><div class="button-tertiary"><div class="text-block text-white">5 mins to read</div><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e548351620549efb48701_White.svg" loading="lazy" alt="" class="arrow-white"/></div></div></div><div class="container-4 w-container"><div class="flex-center"><div class="flex"><div class="margin-right-4"><p class="p-17 text-white text-block">5</p></div><div class="margin-right-4"><p class="p-17 text-block text-white">December</p></div><p class="p-17 text-block text-white">23</p></div></div></div></a><a style="background-color:#68a3a7" href="news-and-publications%3Ffe1439c3_page=2.html#" class="news-card w-inline-block w-condition-invisible"><div class="text-white"><div class="margin-1-bottom"><h4 class="heading-4">Press Release: cambrian Bio Named an Honoree of Fast Company&#x27;s Next Big Things in Tech Award</h4></div><div class="flex-center"><div class="flex"><div class="margin-right-4"><p class="p-17">5</p></div><div class="margin-right-4"><p class="p-17">December</p></div><p class="p-17">23</p></div><div class="button-tertiary"><div class="text-block text-white">5 mins to read</div><div class="text-block text-white"> min read</div><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e548351620549efb48701_White.svg" loading="lazy" alt="" class="arrow-white"/></div></div></div></a></div><div role="listitem" class="collection-item w-dyn-item"><a style="background-color:#164067" href="news-and-publications/amplifier-therapeutics-a-cambrian-bio-pipeline-company-doses-first-patients-in-phase-1b-clinical-trial-and-closes-new-financing-from-future-ventures-and-ra-capital-management.html" class="news-card w-inline-block"><div class="text-white"><div class="margin-1-bottom"><h3>Amplifier Therapeutics, a cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management</h3></div><div class="flex-center"><div class="button-tertiary"><div class="text-block text-white">5 mins to read</div><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e548351620549efb48701_White.svg" loading="lazy" alt="" class="arrow-white"/></div></div></div><div class="container-4 w-container"><div class="flex-center"><div class="flex"><div class="margin-right-4"><p class="p-17 text-white text-block">17</p></div><div class="margin-right-4"><p class="p-17 text-block text-white">October</p></div><p class="p-17 text-block text-white">23</p></div></div></div></a><a style="background-color:#164067" href="news-and-publications%3Ffe1439c3_page=2.html#" class="news-card w-inline-block w-condition-invisible"><div class="text-white"><div class="margin-1-bottom"><h4 class="heading-4">Amplifier Therapeutics, a cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management</h4></div><div class="flex-center"><div class="flex"><div class="margin-right-4"><p class="p-17">17</p></div><div class="margin-right-4"><p class="p-17">October</p></div><p class="p-17">23</p></div><div class="button-tertiary"><div class="text-block text-white">5 mins to read</div><div class="text-block text-white"> min read</div><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e548351620549efb48701_White.svg" loading="lazy" alt="" class="arrow-white"/></div></div></div></a></div><div role="listitem" class="collection-item w-dyn-item"><a style="background-color:#68a3a7" href="news-and-publications/press-release-cambrian-bio-launches-telos-biotech-to-enable-more-robust-cell-therapies.html" class="news-card w-inline-block"><div class="text-white"><div class="margin-1-bottom"><h3>Press Release: cambrian Bio Launches Telos Biotech to Enable More Robust Cell Therapies</h3></div><div class="flex-center"><div class="button-tertiary"><div class="text-block text-white">5 mins to read</div><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e548351620549efb48701_White.svg" loading="lazy" alt="" class="arrow-white"/></div></div></div><div class="container-4 w-container"><div class="flex-center"><div class="flex"><div class="margin-right-4"><p class="p-17 text-white text-block">27</p></div><div class="margin-right-4"><p class="p-17 text-block text-white">June</p></div><p class="p-17 text-block text-white">23</p></div></div></div></a><a style="background-color:#68a3a7" href="news-and-publications%3Ffe1439c3_page=2.html#" class="news-card w-inline-block w-condition-invisible"><div class="text-white"><div class="margin-1-bottom"><h4 class="heading-4">Press Release: cambrian Bio Launches Telos Biotech to Enable More Robust Cell Therapies</h4></div><div class="flex-center"><div class="flex"><div class="margin-right-4"><p class="p-17">27</p></div><div class="margin-right-4"><p class="p-17">June</p></div><p class="p-17">23</p></div><div class="button-tertiary"><div class="text-block text-white">5 mins to read</div><div class="text-block text-white"> min read</div><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e548351620549efb48701_White.svg" loading="lazy" alt="" class="arrow-white"/></div></div></div></a></div></div></div></div></div><div class="container w-container"><div class="div-block-5"><a href="news-and-publications%3Ffe1439c3_page=2.html#In-the-news" class="in-the-news-button btn w-button">See cambrian in the news</a></div></div></section><section class="s s-newspublicationslisting"><div class="c"><h1 class="heading-5">Press R<strong>eleases</strong></h1><div class="pc pc-60 _40-ld"><div class="w-dyn-list"><div role="list" class="list w-dyn-items"><div role="listitem" class="item w-dyn-item"><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-external w-inline-block w-condition-invisible"></a><a href="news-and-publications/test-press-release-cambrian-biopharma-announces-licensing-agreement-to-develop-selective-mtor-inhibitors.html" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">5 mins to read</p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">16</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">22</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Press Release: cambrian BioPharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">mTOR inhibitors prevent age-related physiologic decline and lengthen healthspan. Licensed compounds will be developed by new cambrian subsidiary Tornado Therapeutics, led by Joan Mannick, M.D. as CEO.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>See More</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e57edef84bb403117ccd4_Vector.svg" loading="lazy" alt="" class="arrow-black"/></div><div class="cta w-condition-invisible"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-external w-inline-block w-condition-invisible"></a><a href="news-and-publications/test-press-release-cambrian-biopharma-closes-100-million-series-c-to-advance-healthspan-boosting-therapeutics-to-the-clinic.html" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">5 mins to read</p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">26</p></div><div class="margin-right-4"><p class="p-17">October</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Press Release: cambrian BioPharma Closes $100 Million Series C to Advance Healthspan-boosting Therapeutics to the Clinic</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Financing co-led by Anthos Capital and SALT Fund; Anthos’s Paul Farr and biotech leader Brent Saunders to join Board of Directors.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>See More</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e57edef84bb403117ccd4_Vector.svg" loading="lazy" alt="" class="arrow-black"/></div><div class="cta w-condition-invisible"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div></div><div role="navigation" aria-label="List" class="w-pagination-wrapper"><a href="news-and-publications%3Ffe1439c3_page=1.html" aria-label="Previous Page" class="w-pagination-previous"><svg class="w-pagination-previous-icon" height="12px" width="12px" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 12" transform="translate(0, 1)"><path fill="none" stroke="currentColor" fill-rule="evenodd" d="M8 10L4 6l4-4"></path></svg><div class="w-inline-block">Previous</div></a><div aria-label="Page 2 of 2" role="heading" class="w-page-count page-count">2 / 2</div></div></div></div></div></section><div id="In-the-news" class="in-the-news-section"><div class="w-container"><h1 class="heading-5">In the News</h1></div><div class="container-2 w-container"><div class="pc pc-60 _40-ld"><div class="w-dyn-list"><div role="list" class="list w-dyn-items"><div role="listitem" class="item w-dyn-item"><a href="https://www.biotech2050.com/episodes/new-vision-for-preventing-amp-curing-age-related-diseases-james-peyer-founder-amp-ceo-cambrian-bio" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Biotech 2050 Podcast</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">28</p></div><div class="margin-right-4"><p class="p-17">June</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">New Vision for Preventing &amp; Curing Age-Related Diseases</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Insights from our CEO James Peyer, about his personal journey in the field, his vision for cambrian and his perspective on potential hurdles in the space. </p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.wsj.com/articles/rapamycin-anti-aging-drug-longevity-a27575f4?st=27ffynn0dpchk7q&amp;reflink=desktopwebshare_permalink" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">WSJ</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">1</p></div><div class="margin-right-4"><p class="p-17">May</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Can a Kidney Transplant Drug Keep You From Aging?</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Some people looking to extend their lifespan have for years turned to a decades-old diabetes drug, metformin. Now, rapamycin, an immunosuppressant medication, is capturing their attention because some aging researchers believe it holds more promise.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://proto.life/2023/04/the-stepping-stone-approach-to-getting-longevity-drugs-to-market/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">proto.life</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">20</p></div><div class="margin-right-4"><p class="p-17">April</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">The &quot;Stepping Stone&quot; Approach To Getting Longevity Drugs To Market</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">The &quot;Stepping Stone&quot; approach is a new approach to bring longevity drugs to the market. This approach involves first developing drugs that target age-related diseases such as Alzheimer&#x27;s and cardiovascular disease, which are more likely to gain regulatory approval. Once these drugs are approved, they can be used to validate the concept of longevity drugs and pave the way for the development of more specific anti-aging drugs. </p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.biospace.com/article/amplifier-launches-to-bring-first-ampk-activator-for-obesity-to-clinic/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">BioSpace</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">14</p></div><div class="margin-right-4"><p class="p-17">March</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Amplifier Launches to Bring First AMPK Activator to the Clinic</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian Bio unveils a new pipeline company, Amplifier Therapeutics which is focused on developing a clinical-stage AMPK activator with broad potential. </p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://endpts.com/exercise-in-a-pill-thats-the-focus-of-cambrians-new-pipeline-company/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Endpoints News</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">14</p></div><div class="margin-right-4"><p class="p-17">March</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Exercise in a pill? That&#x27;s the focus of cambrian&#x27;s new pipeline company</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian BioPharma has a new clinical candidate to work with, going after what CEO James Peyer described as a “Holy Grail target.”</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://longevity.technology/news/cambrian-bio-reveals-new-pipeline-company-with-focus-on-ampk-activation/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Longevity.Technology</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">14</p></div><div class="margin-right-4"><p class="p-17">March</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">cambrian Bio reveals new pipeline company with focus on AMPK activation</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian Bio, a clinical-stage biotech focused on treating and preventing chronic diseases of aging, has announced the launch of its new pipeline company, Amplifier Therapeutics.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://fortune.com/well/2023/02/23/reverse-aging-breakthroughs-in-science/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Fortune Well</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">23</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Is reverse aging already possible? Drugs that could treat aging might already be on the pharmacy shelves</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Drugs that could lower risk for multiple age-related diseases at once and, perhaps, treat aging as a whole, might already be on the shelves of the pharmacy. </p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast/play/32-cambrian-carves-out-a-new-niche-as-it-works-to-keep-people-from-getting-sick" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">BioWorld</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">21</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">cambrian carves out a new niche as it works to keep people from getting sick</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian CEO James Peyer joins the BioWorld team on the BioWorld podcast to talk about how cambrian is working to extend healthspan by developing interventions that treat specific diseases to then deploying them as preventative medicines to improve our quality of life as we age.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.statnews.com/2023/01/30/scientists-ceos-founders-trying-to-make-longevity-mainstream/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">STAT News</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">30</p></div><div class="margin-right-4"><p class="p-17">January</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">No more ‘playing God’: How the longevity field is trying to recast its work as serious science</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">CEOs, and founders are aiming to make longevity a mainstream concept. They believe that with advances in technology, it is possible to extend human lifespan and improve the quality of life for older individuals.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://endpts.com/nih-associate-director-announces-departure-to-private-sector-joining-anti-aging-biotech/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Endpoints News</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">25</p></div><div class="margin-right-4"><p class="p-17">January</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">NIH associate director announces departure to private sector, joining anti-aging biotech</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">The associate director of the National Institute of Health’s Office of Legislative Policy and Analysis (OLPA) is leaving her government post to join CEO James Peyer at cambrian BioPharma.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.biospace.com/article/cambrian-unveils-latest-longevity-pipeline-company-isterian/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">BioSpace</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">13</p></div><div class="margin-right-4"><p class="p-17">January</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">cambrian Unveils Latest Longevity Pipeline Company: Isterian</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Multi-asset firm cambrian Biopharma announced Thursday that its latest pipeline company, Isterian Biotech, has emerged from stealth to develop first-in-class medicines to tackle aging. </p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://endpts.com/cambrians-anti-aging-mission-expands-with-new-fibrotic-disease-biotech/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Endpoints News</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">12</p></div><div class="margin-right-4"><p class="p-17">January</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">cambrian&#x27;s anti-aging mission expands with new fibrotic disease biotech</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian BioPharma has a new pipeline company focused on the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during aging resulting in fibrotic diseases.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://longevity.technology/news/cambrian-biopharma-unveils-new-pipeline-company/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Longevity.Technology</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">12</p></div><div class="margin-right-4"><p class="p-17">January</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">cambrian BioPharma unveils new pipeline company</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Isterian Biotech will focus on developing novel drugs to stop and reverse the pathological accumulation of crosslinked proteins commonly observed in all major organs with age.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.ft.com/content/649b0446-698c-4363-82ad-0be5b5faa68f?accessToken=zwAAAYV-8Mcwkc9kmwRGaYxDY9OCrQvltfqmjw.MEQCIER8gjUjTtYiWflo5xlE36DqtsWJ9rZp1jUgPoZYdI84AiBqjh46HLjLmNw2DdcZ_7tmGhkxA3Ww0yhgN_0gExYsYQ&amp;sharetype=gift&amp;token=a6366032-60be-4d20-a88d-21d7a13317c8" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">The Financial Times</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">2</p></div><div class="margin-right-4"><p class="p-17">January</p></div><p class="p-17">23</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">The start-ups seeking a cure for old age</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Tech billionaires are funding research to help us live longer and healthier lives. cambrian CEO James Peyer weighs in and shares his approach to longevity. </p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.statnews.com/2022/08/09/anti-aging-projects-funding-much-discussed-trial-overlooked/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">STAT News</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">9</p></div><div class="margin-right-4"><p class="p-17">August</p></div><p class="p-17">22</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">In the lab with James Peyer - From the STAT Report “The race for longevity: How scientists — and industry — are seeking to extend healthy lives.”</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked. cambrian BioPharma CEO James Peyer weighs in on the TAME trial.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://endpts.com/a-new-spinout-wades-into-ovarian-aging-armed-with-a-seed-round-and-experimental-drugs-from-mass-general/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Endpoints News</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">20</p></div><div class="margin-right-4"><p class="p-17">May</p></div><p class="p-17">22</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">A new spinout wades into ovarian aging, armed with a seed round and experimental drugs from Mass General</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Oviva Therapeutics, a pipeline company of New York-based cambrian Biopharma, emerged from stealth to dive into the idea of extending women’s “healthspans,” or what it says is the part of a person’s life spent in generally good health, with a specific focus on ovaries.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.bostonglobe.com/2022/05/19/business/this-startup-aims-make-contraceptives-that-prolong-fertility-delay-menopause-improve-womens-health/?event=event12" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Boston Globe</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">19</p></div><div class="margin-right-4"><p class="p-17">May</p></div><p class="p-17">22</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">This startup aims to delay menopause and prolong fertility with a new contraceptive</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Oviva Therapeutics, a cambrian Bio PipeCo, just raised $11.5 million to develop drugs based on the work of Mass. General researchers.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://podcasts.apple.com/us/podcast/james-peyer-on-unorthodox-ideas/id1453893304?i=1000563241026" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Hello Monday</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">25</p></div><div class="margin-right-4"><p class="p-17">April</p></div><p class="p-17">22</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">James Peyer on unorthodox ideas on Hello Monday with Jessi Hempel </h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Like a lot of successful entrepreneurs, James Peyer is a bit of an outlier. He thinks about something differently: Aging. To James, aging is a curable illness, something to be treated or prevented. He sits down with Jessi for a conversation on what led him to create cambrian Biopharma, and why unorthodox ideas are so critical to the development of society and culture.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.youtube.com/watch?v=hQ4EbnTBOec&amp;t=223s&amp;ab_channel=BloombergQuicktake%3AOriginals" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Bloomberg</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">22</p></div><div class="margin-right-4"><p class="p-17">April</p></div><p class="p-17">22</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">The $7.6 Trillion Quest for Longer Life</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">The new field of longevity science aims to slow aging and make late-life more livable. But will the science ever work? And if so, will it only be for the super rich?</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://longevity.technology/news/new-mtor-player-storms-into-longevity/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Longevity.Technology</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">3</p></div><div class="margin-right-4"><p class="p-17">March</p></div><p class="p-17">22</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">New mTOR player storms into longevity</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Dr. Joan Mannick, CEO of Tornado Therapeutics, a cambrian Bio PipeCo, says rapamycin is better validated than any other therapeutic for targeting aging and extending lifespan.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.biocentury.com/article/642300/cambrian-launches-new-subsidiary-to-develop-mtor-inhibitors" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">BioCentury</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">16</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">22</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">cambrian launches new subsidiary to develop mTOR inhibitors</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian Bio has added to its age-related disease portfolio via a deal with Novartis for a series of mTOR inhibitors that will be developed by newly launched subsidiary Tornado Therapeutics.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.cnbc.com/video/2021/12/22/biotech-will-continue-to-be-a-great-spot-for-investment-cambrian-biopharma-ceo.html" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">CNBC</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">22</p></div><div class="margin-right-4"><p class="p-17">December</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Biotech will continue to be a great spot for investment: cambrian BioPharma CEO</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">James Peyer, our co-founder and CEO, joins CNBC’s ‘Squawk Box’ to discuss what investors need to know about the growing longevity industry.
</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.bloomberg.com/news/videos/2021-10-26/the-startup-that-may-hold-the-key-to-extending-human-life-video" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Bloomberg</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">27</p></div><div class="margin-right-4"><p class="p-17">October</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">The Startup That May Hold the Key to Extending Human Life</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Our CEO James Peyer discusses the longevity startup&#x27;s development of therapeutics to fight age-related diseases. He speaks with Bloomberg&#x27;s Matt Miller on &quot;Bloomberg Markets.&quot;</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.fiercebiotech.com/biotech/cambrian-secures-100m-series-c-for-atai-roivant-like-approach-to-building-up-biotechs-14" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Fierce Biotech</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">26</p></div><div class="margin-right-4"><p class="p-17">October</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">cambrian secures $100M series C for Roivant-like approach to biotech creation with goal to slow down human aging</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian will likely test two of its first three compounds in rare childhood disorders &quot;because the mechanisms work a little bit like fast-aging syndromes,&quot; said James Peyer, Ph.D., CEO and co-founder of the biotech.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://thehealthcaretechnologyreport.com/the-top-25-women-leaders-in-biotechnology-of-2021/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">THTR</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">20</p></div><div class="margin-right-4"><p class="p-17">October</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Juliette Han - The Top 25 Women Leaders in Biotechnology of 2021</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian BioPharma Chief Operating Officer, Juliette Han, PhD named as one of the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.youtube.com/watch?v=lygY26hQ8yw" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Rational Mind</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">19</p></div><div class="margin-right-4"><p class="p-17">July</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">&quot;Rational Mind&quot; with Pietro Boselli - Episode 4: Longevity (featuring James Peyer)</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">&quot;Rational Mind&quot;, a science series hosted by engineer and influencer Pietro Boselli, aims to inspire viewers to use rationality and critical thinking to approach complex issues. In this episode, James discusses the longevity science space and the opportunities and challenges ahead.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="http://agingpharma.org/speakers" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">AARD</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">15</p></div><div class="margin-right-4"><p class="p-17">July</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">James Peyer to present at the 8th Aging Research &amp; Drug Discovery Meeting 2021</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">James Peyer to present new research in the biology of aging at the world&#x27;s largest Aging Research for Drug Discovery conference.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.youtube.com/watch?v=-55-pjufl-s" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">CogX</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">16</p></div><div class="margin-right-4"><p class="p-17">June</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">CogX Festival 2021: &quot;Death is just a Technical Problem&quot; Panel Discussion with James Peyer</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">Does anyone really want to live until 180? Progress in longevity science is abundant at the moment, from healthspan hacking to novel therapies being brought under development. Our panel of experts discuss the philosophical and scientific innovations taking place at the cutting edge of the life-extensionists field and what implications they could have for us all.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.pm360online.com/cambrian-is-using-a-new-drug-discovery-model-to-solve-the-science-of-aging/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">PM 360</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">26</p></div><div class="margin-right-4"><p class="p-17">April</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">PM360: cambrian is Using a New Drug Discovery Model to Solve the Science of Aging</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian BioPharma is one of the newly emerging distributed drug discovery companies that applies a new twist to investing in interesting science. PM360 spoke with co-founder James Peyer about this new model, why he decided to focus on the biology of aging, and more.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.youtube.com/watch?v=AnK7AFc2cj4&amp;t=1s" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Foresight Institute</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">14</p></div><div class="margin-right-4"><p class="p-17">April</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Foresight Institute Biotech &amp; Health Extension Webinar: “James Peyer: How to Fund and Build Geroprotectors”</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">In this session, James Peyer, PhD, CEO of cambrian BioPharma, shares his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how cambrian functions, what is a &quot;DisCo model&quot; (and why it will most likely replace single asset biotech companies model), and the barriers preventing us from starting clinical trials with the first geroprotectors.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.longevity.technology/cambrian-biopharma-james-peyer-qa/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Longevity Technology</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">23</p></div><div class="margin-right-4"><p class="p-17">March</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Longevity.Technology: cambrian BioPharma – CEO James Peyer Q&amp;A</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">An exclusive Q&amp;A with cambrian BioPharma’s CEO, James Peyer – a discussion of the Hallmarks of Aging and classifying aging as a disease.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.nature.com/articles/s41573-021-00139-y" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Nature Briefing</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">1</p></div><div class="margin-right-4"><p class="p-17">March</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Nature Reviews Drug Discovery (May 2021 Cover Story): Strategies for delivering therapeutics across the blood–brain barrier (Georg C. Terstappen; EVP, Drug Discovery)</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">A review of recent developments and challenges related to selected blood–brain barrier-crossing strategies — with a focus on non- invasive approaches such as receptor-mediated transcytosis and the use of neurotropic viruses, nanoparticles and exosomes — and analysis of their potential in the treatment of CNS disorders.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://podcasts.apple.com/us/podcast/the-pomp-podcast/id1434060078?i=1000509663184" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">The Pomp Podcast</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">18</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">The Pomp Podcast with Anthony Pompliano: James Peyer on Longevity and Curing Cance‪r‬</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">James Peyer is the Co-Founder and CEO of cambrian BioPharma, a Distributed Development Company developing therapeutics targeting the biology of aging. cambrian builds, finances, and manages a pipeline of therapeutics. In this conversation, we discuss molecular damage, adding healthy years to your life, prevention vs reversal of diseases, and distributed drug companies.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.longevity.technology/international-day-of-women-and-girls-in-science/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Longevity Technology</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">11</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Longevity.Technology: International Day of Women and Girls in Science</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">In 2015, The UN declared February 11th the “International Day of Women and Girls in Science.&quot; Today marks the sixth celebration of the vital role women and girls play in science, technology and innovation. We are delighted to showcase some of the women whose work we have covered or will be covering and to play our part in promoting women and girls in science.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://trialsitenews.com/anti-aging-distributed-drug-discovery-venture-cambrian-biopharma-announces-60m-funding-first-ipo-of-portfolio-company/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">TrialSite News</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">11</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">TrialSite News: Anti-Aging Distributed Drug Discovery Venture cambrian BioPharma Announces $60m Funding &amp; First IPO of Portfolio Company</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian BioPharma, a new type of biotech venture raising $60 million to execute on a model known as the “Distributed Development Company” or “DisCo,” that is, a multi-asset company combining the advantages of the standard biotech firm with those of a venture capital fund and biotech incubator, to establish a platform for the development of new anti-aging therapeutics.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://www.longevity.technology/cambrian-biopharma-exits-stealth-with-60m-and-affiliate-ipo/" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Longevity Technology</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">9</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Longevity.Technology: cambrian BioPharma exits stealth with $60m and affiliate IPO</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">cambrian BioPharma, a distributed development company, exits stealth mode with the announcement that it has raised $60 million in private financing to develop medicines to extend healthy lifespan.</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div><div role="listitem" class="item w-dyn-item"><a href="https://pubs.rsc.org/en/content/articlepdf/2021/na/d0na00879f" target="_blank" class="link-external w-inline-block"></a><a href="news-and-publications%3Ffe1439c3_page=2.html#" class="link-block w-inline-block"><div class="flex block-tb"><div class="col-news"><div class="flex margin-right-tb"><p class="medium">Royal Society of Chem.</p><p class="medium w-dyn-bind-empty"></p></div><div class="pc pc-4"><div class="flex"><div class="margin-right-4"><p class="p-17">9</p></div><div class="margin-right-4"><p class="p-17">February</p></div><p class="p-17">21</p></div></div></div><div class="grow"><div class="clamp clamp2"><h3 class="h2-h3">Nanoscale Advances (May 2021 Cover Story): Trafficking of JC virus-like particles across the blood–brain barrier (Georg C. Terstappen; EVP, Drug Discovery)</h3></div><div class="pc pc-15 _10-ld"><div class="clamp"><p class="p-17">A study on John Cunningham virus-like particles (JC VLPs) and their potential use in developing a delivery system for transport of genes and small molecule cargoes across the blood-brain barrier (BBB).</p></div></div></div><div class="col-news"><div class="center"><div class="cta"><p>Visit</p><img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/616e5d96dcf8fd4f8976dca0_60fb8aa8d7a30b7a8bfb7e0d_Vector%20(2).svg" loading="lazy" alt="" class="arrow-black"/></div></div></div></div></a></div></div></div></div></div></div></main><footer tabindex="0" class="footer"><div class="s overflow"><div class="c"><div class="footer-c1"><div class="abs abs-footer w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="641" height="707" viewBox="0 0 641 707" fill="none"><path d="M354.374 82.496c-35.704 0-69.787 6.971-100.963 19.628l-3.479-8.54-.464.189C147.839 135.262 76.204 235.231 76.204 351.963c0 153.916 124.54 278.689 278.17 278.689 76.64 0 146.042-31.051 196.352-81.282l.354-.354-6.523-6.504c4.175-4.183 8.215-8.503 12.11-12.953 12.109-13.835 33.326-16.657 47.005-4.508l36.661 32.572C576.491 647.715 471.516 706.5 352.84 706.5 158.249 706.5.5 548.458.5 353.5S158.249.5 352.84.5C461.497.5 558.667 49.777 623.3 127.244l-34.623 33.601c-12.802 12.425-33.477 10.972-46.279-1.568-48.493-47.502-114.844-76.781-188.024-76.781zM86.409 351.963c0-112.276 68.793-208.454 166.454-248.535l19.586 48.078c6.297 15.454-1.276 32.96-15.54 41.777-12.231 7.561-23.523 16.5-33.66 26.602l-6.55-6.563-.354.355c-35.31 35.416-57.147 84.32-57.147 138.332 0 108.102 87.471 195.74 195.376 195.74 26.256 0 51.305-5.19 74.179-14.602l.46-.189-3.461-8.541c12.978-5.392 25.211-12.212 36.51-20.263 13.595-9.688 32.522-9.881 44.272 1.843l36.607 36.515c-48.435 48.162-115.133 77.918-188.767 77.918-27.697 0-54.411-4.209-79.54-12.024-10.826-3.369-21.358-7.403-31.547-12.061C150.735 554.05 86.409 460.531 86.409 351.963zm323.26 135.452l14.779 36.45c-21.56 8.808-45.151 13.662-69.874 13.662-102.267 0-185.172-83.057-185.172-185.518a186.35 186.35 0 0 1 5.215-43.901c8.064-33.297 25.098-63.085 48.393-86.648l.198-.2 30.414 30.47c11.764 11.786 11.372 30.85 3.098 45.49-9.373 16.586-14.723 35.753-14.723 56.172 0 63.051 51.019 114.168 113.957 114.168 4.419 0 8.78-.254 13.066-.741 16.688-1.912 34.385 5.149 40.649 20.596z" stroke="url(#A)"/><defs><linearGradient id="A" x1="320.5" y1="0" x2="320.5" y2="707" gradientUnits="userSpaceOnUse"><stop stop-color="#081b42" stop-opacity="0"/><stop offset=".255" stop-color="#109e5a"/><stop offset=".531" stop-color="#36c"/><stop offset=".771" stop-color="#d8a76e"/><stop offset="1" stop-color="#081b42" stop-opacity="0"/></linearGradient></defs></svg></div><div tabindex="0" class="c c-260-prt"><h3 class="p-32">We want to hear from you.</h3><div tabindex="0" class="pc pc-30"><a aria-label="Contact us (opens in a new tab)" tabindex="0" href="contact.html" target="_blank" class="btn w-button">Contact us</a></div></div></div></div></div><div class="s"><div class="c"><div class="footer-c2"><div class="left-110"><div class="flex flex-center block-prt"><a href="index.html" aria-label="home" class="w-inline-block"><div class="w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="7.1875em" height="1.25em" viewBox="0 0 115 20" fill="currentColor"><path d="M104.144 7.712a5.74 5.74 0 0 1 3.918-1.489 6.14 6.14 0 0 1 2.638.589c.823.389 1.543.956 2.107 1.657.836 1.029 1.28 2.327 1.28 4.518v6.226h-2.641v-6.377c0-1.626-.304-2.382-.776-2.951a3.44 3.44 0 0 0-1.199-.91c-.464-.213-.971-.322-1.484-.32a4.92 4.92 0 0 0-2.083.495 4.79 4.79 0 0 0-1.657 1.327v8.736h-2.641V6.496h2.557l-.019 1.216zM36.15 6.559V7.78c1.04-.948 2.409-1.48 3.833-1.489.881-.005 1.752.182 2.549.547s1.501.898 2.06 1.562a6.54 6.54 0 0 1 2.246-1.577c.855-.364 1.781-.545 2.714-.532a6.04 6.04 0 0 1 2.569.552 5.89 5.89 0 0 1 2.068 1.584c.804.975 1.192 2.218 1.192 4.359v6.49h-2.637V12.38c0-1.303-.276-2.004-.748-2.546a3.2 3.2 0 0 0-1.098-.815c-.423-.191-.882-.291-1.347-.291a5.49 5.49 0 0 0-2.187.497 5.36 5.36 0 0 0-1.787 1.325 10.14 10.14 0 0 1 .234 2.236v6.49h-2.637V12.38c0-1.303-.28-2.004-.753-2.546-.315-.35-.703-.63-1.139-.821s-.908-.288-1.386-.286c-.709.03-1.403.209-2.035.523s-1.188.757-1.63 1.299v8.727H33.59V6.559h2.557zM9.817.001c1.33-.014 2.648.238 3.874.741a9.71 9.71 0 0 1 3.25 2.183L15.754 4.1a.95.95 0 0 1-1.225.082C13.187 3.147 11.528 2.58 9.817 2.57c-3.974 0-7.054 3.088-7.054 7.169 0 4.277 3.165 7.174 7.302 7.174 1.891-.034 3.697-.774 5.044-2.068a.95.95 0 0 1 1.257 0l1.253 1.116c-.915 1.092-2.067 1.974-3.373 2.582a10.03 10.03 0 0 1-4.181.934C4.277 19.481 0 15.341 0 9.739 0 4.277 4.207.001 9.817.001zm69.715 7.87a.85.85 0 0 1-.069.335.87.87 0 0 1-.196.283c-.084.081-.183.145-.293.188s-.227.065-.345.064a4.62 4.62 0 0 0-2.202.582 4.47 4.47 0 0 0-1.631 1.554v8.335h-2.641V6.496h2.557v1.512a4.9 4.9 0 0 1 1.774-1.254 5.02 5.02 0 0 1 2.158-.376c.297-.002.594.016.888.055v1.439zM82.421.269a1.79 1.79 0 0 1 .672.129 1.75 1.75 0 0 1 .569.37 1.7 1.7 0 0 1 .38.555 1.66 1.66 0 0 1 .132.654 1.64 1.64 0 0 1-.137.646 1.68 1.68 0 0 1-.382.545 1.73 1.73 0 0 1-.568.359 1.76 1.76 0 0 1-.666.117 1.73 1.73 0 0 1-.663-.12 1.69 1.69 0 0 1-.562-.363 1.66 1.66 0 0 1-.372-.548 1.61 1.61 0 0 1-.123-.646 1.64 1.64 0 0 1 .124-.648c.085-.206.211-.393.371-.552a1.7 1.7 0 0 1 .561-.369 1.76 1.76 0 0 1 .664-.13zm-1.304 6.226h2.641v12.717h-2.641V6.496zm-52.512.001v8.736a4.49 4.49 0 0 1-1.57 1.322c-.621.316-1.31.487-2.011.5-.569.01-1.134-.092-1.663-.298a4.27 4.27 0 0 1-1.412-.905c-.404-.391-.724-.856-.94-1.369s-.325-1.063-.319-1.618c0-2.218 1.58-4.195 3.702-4.195a3.19 3.19 0 0 1 1.575.355.96.96 0 0 0 .584.11c.202-.026.389-.116.534-.255l1.402-1.366a6.24 6.24 0 0 0-3.885-1.284c-1.12-.013-2.222.267-3.193.811-1.031.602-1.883 1.456-2.471 2.476s-.894 2.174-.885 3.344c-.013 1.164.287 2.311.872 3.327a6.74 6.74 0 0 0 2.457 2.462 6.82 6.82 0 0 0 3.272.838 6.09 6.09 0 0 0 4.03-1.435v1.166h2.552V6.496h-2.632zm67.461-.119V15.1c-.412.553-.949 1.005-1.571 1.321a4.63 4.63 0 0 1-2.01.501 4.36 4.36 0 0 1-1.663-.3 4.27 4.27 0 0 1-1.412-.906 4.15 4.15 0 0 1-.939-1.37 4.06 4.06 0 0 1-.319-1.618c0-2.218 1.585-4.195 3.707-4.195.546-.017 1.088.106 1.571.355a.96.96 0 0 0 .584.11c.202-.026.389-.116.534-.255l1.402-1.366c-1.005-.74-2.211-1.178-3.469-1.259a6.6 6.6 0 0 0-3.609.803 6.79 6.79 0 0 0-2.474 2.473c-.589 1.021-.895 2.173-.887 3.344a6.51 6.51 0 0 0 .872 3.329c.585 1.016 1.434 1.864 2.461 2.46a6.81 6.81 0 0 0 3.272.838c1.477.022 2.911-.489 4.025-1.435v1.166h2.552V6.377h-2.627zm-28.978.656c-.971-.544-2.073-.824-3.193-.811a6.15 6.15 0 0 0-3.922 1.366l1.309 1.339a.94.94 0 0 0 .53.274.96.96 0 0 0 .592-.096 3.34 3.34 0 0 1 1.543-.373c2.211 0 3.861 1.904 3.861 4.099.006.554-.103 1.104-.319 1.616s-.535.978-.938 1.369a4.27 4.27 0 0 1-1.411.905 4.36 4.36 0 0 1-1.661.3c-.702-.012-1.391-.182-2.014-.498a4.49 4.49 0 0 1-1.572-1.323V0h-2.636v19.212h2.58v-1.166c1.113.947 2.547 1.458 4.025 1.435a6.83 6.83 0 0 0 3.272-.838c1.027-.596 1.875-1.445 2.46-2.461a6.52 6.52 0 0 0 .873-3.328c.007-1.173-.301-2.328-.894-3.349a6.81 6.81 0 0 0-2.486-2.472z"/></svg></div></a><div class="copyright"><p class="p-17 regular">© 2023 cambrian® BioPharma, Inc. All rights reserved.</p></div></div></div><div class="right-110"><div class="flex flex-center block-prt"><a href="privacy-policy.html" tabindex="0" class="link link-footer">Policies</a><a href="news-and-publications.html" tabindex="0" rel="noopener" aria-current="page" class="link link-footer w--current">Press</a><div class="flex flex-justify-center"><a tabindex="0" aria-label="linkedin" rel="noopener" href="https://www.linkedin.com/company/cambrianbio/about/" target="_blank" class="link-social w-inline-block"><div class="w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="1.0625em" height="1em" viewBox="0 0 17 16" fill="#e2ecff"><path d="M16.328 15.874a61.67 61.67 0 0 0-2.93 0c-.211 0-.258-.046-.258-.255V10.44c0-.395-.023-.79-.141-1.161-.352-1.207-1.758-1.649-2.766-.836-.539.418-.75.998-.75 1.695v4.876c0 .209-.023.418 0 .65.023.186-.07.232-.234.209h-3c-.187 0-.234-.046-.234-.232l.023-4.412-.023-5.41c0-.209.047-.255.234-.255h3c.188 0 .234.046.234.232V6.98l.117-.116c.914-1.324 2.203-1.695 3.727-1.463 1.758.279 2.883 1.486 3.164 3.344.07.441.094.882.094 1.324v5.55c0 .186-.047.255-.258.255zM4.141 10.719v4.876c0 .209-.047.279-.258.279-.984-.023-1.969 0-2.953 0-.187 0-.234-.046-.234-.232V5.796c0-.163.047-.232.234-.232h3.023c.211 0 .234.07.234.255l-.047 4.9zm.164-7.849c-.234.929-1.195 1.463-2.297 1.277C.836 3.962.18 2.824.602 1.709.883 1.013 1.562.595 2.43.618 3.742.595 4.609 1.64 4.305 2.87z"/></svg></div></a><a tabindex="0" aria-label="twitter" rel="noopener" href="https://mobile.twitter.com/cambrianbio" target="_blank" class="link-social w-inline-block"><div class="w-embed"><svg xmlns="http://www.w3.org/2000/svg" width="1em" height="0.875em" viewBox="0 0 16 14" fill="none"><path d="M14.387 4.131v.415c0 4.293-3.309 9.25-9.34 9.25-1.864 0-3.581-.539-5.047-1.452.251.021.524.041.775.041 1.529 0 2.953-.518 4.084-1.39-1.445-.021-2.66-.975-3.058-2.261a3.07 3.07 0 0 0 .628.062c.293 0 .586-.041.859-.124C1.78 8.383.649 7.077.649 5.5v-.041a3.25 3.25 0 0 0 1.487.415A3.25 3.25 0 0 1 .67 3.157c0-.601.168-1.161.44-1.638 1.613 1.97 4.042 3.256 6.764 3.401-.063-.228-.084-.498-.084-.747 0-1.804 1.466-3.256 3.288-3.256.942 0 1.801.394 2.387 1.016.754-.145 1.445-.415 2.094-.788-.251.767-.775 1.39-1.445 1.804.67-.083 1.298-.249 1.885-.518-.419.664-.963 1.244-1.613 1.701z" fill="#e2ecff"/></svg></div></a></div></div></div></div></div></div></footer><div class="cookie-script w-embed w-script"><script type="text/javascript" charset="UTF-8" src="http://cdn.cookie-script.com/s/d908b12cd9c87fea4284a4185b750faa.js"></script></div><div class="accessibility-widget w-embed w-script"><div id="accessibility-widget">
  <div id="widget-button" role="button" tabindex="0" aria-label="Open Accessibility Options" onkeydown="handleButtonKey(event)">
    <img src="https://cdn.prod.website-files.com/600be113c4111047016de64a/66d6024aa7544dcc894d9c9d_Accessibility%20icon.svg" alt="Accessibility Icon">
</div>
    <div id="settings-panel">
        <button id="increase-font">Zoom In</button>
        <button id="decrease-font">Zoom Out</button>
        <button id="toggle-contrast">Toggle Contrast</button>
    </div>
</div>

<style>
    #accessibility-widget {
        position: fixed;
        bottom: 70px;
        left: 15px;
        z-index: 1000;
    }

    #widget-button {
        background-color: #fff;
        width: 40px;
        height: 40px;
        border-radius: 50%;
        display: flex;
        align-items: center;
        justify-content: center;
        cursor: pointer;
        box-shadow: 0 2px 5px rgba(0, 0, 0, 0.3);
    }

    #widget-button img {
        width: 24px;
        height: 24px;
    }

    #settings-panel {
        display: none;
        flex-direction: column;
        align-items: center;
        margin-top: 10px;
        background-color: #f1f1f1;
        border-radius: 5px;
        padding: 10px;
        box-shadow: 0 2px 5px rgba(0, 0, 0, 0.3);
    }

    #settings-panel button {
        margin: 5px 0;
        padding: 5px 10px;
        font-size: 14px;
        cursor: pointer;
        width: 100%;
        background-color: #fff;
        color: #000;
        border: 1px solid #000;
        border-radius: 5px;
        box-shadow: 0 1px 3px rgba(0, 0, 0, 0.2);
    }

    .high-contrast {
        background-color: #000 !important;
        color: #fff !important;
    }

    .high-contrast .Nav, .high-contrast .navlink {
        color: #fff !important;
        background-color: #000 !important;
    }

    /* Mobile-specific styles */
    @media (max-width: 767px) {
        #accessibility-widget {
            bottom: 20px;
            left: 10px;
        }

        #widget-button {
            width: 30px;
            height: 30px;
        }

        #widget-button img {
            width: 18px;
            height: 18px;
        }

        #settings-panel button {
            padding: 5px;
        }

        html {
            overflow-x: hidden;
        }
    }
</style>

<script>
    document.addEventListener("DOMContentLoaded", function() {
        const widgetButton = document.getElementById('widget-button');
        const settingsPanel = document.getElementById('settings-panel');
        let fontSize = 16;

        widgetButton.addEventListener('click', function() {
            if (settingsPanel.style.display === 'none' || settingsPanel.style.display === '') {
                settingsPanel.style.display = 'flex';
            } else {
                settingsPanel.style.display = 'none';
            }
        });

        document.getElementById("increase-font").addEventListener("click", function() {
            fontSize += 2;
            document.body.style.fontSize = fontSize + 'px';
        });

        document.getElementById("decrease-font").addEventListener("click", function() {
            fontSize -= 2;
            document.body.style.fontSize = fontSize + 'px';
        });

        document.getElementById("toggle-contrast").addEventListener("click", function() {
            document.body.classList.toggle('high-contrast');
            document.querySelector('.Nav').classList.toggle('high-contrast');
            document.querySelectorAll('.navlink').forEach(function(link) {
                link.classList.toggle('high-contrast');
            });
        });
    });
</script></div><script src="https://d3e54v103j8qbb.cloudfront.net/js/jquery-3.5.1.min.dc5e7f18c8.js?site=600be113c4111047016de64a" type="text/javascript" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script><script src="https://cdn.prod.website-files.com/600be113c4111047016de64a/js/webflow.0527a82382a637c47b9102f8ac6f9982.js" type="text/javascript"></script><script>
// PAGE TRANSITION
function tr(myLink) {
    return (myLink.host == window.location.host);
}
$('a:not(.w-pagination-next)').each(function() {
  if (tr(this) && (this).href.indexOf('#') === -1) {
  $(this).click(function(e){
  e.preventDefault();
  var moduleURL = jQuery(this).attr("href");
  setTimeout( function() { window.location = moduleURL }, 350 );
  $('.tr').css("opacity", "1");
});
    }
});
  $(window).bind("pageshow", function(event) {
    if (event.originalEvent.persisted) {
        window.location.reload() 
    }
});

// NAV INTERACTIONS
$('.menu-btn').click(function() {
$('.nav').toggleClass('nav-open');
});
  
// LOCK SCROLL - MENU OPEN
(function(){$(".menu-btn").click(function(){$("body").toggleClass("overflow")})}).call(this),function(){var t=document.getElementById("menu"),e=null;t.addEventListener("touchstart",function(t){1===t.targetTouches.length&&(e=t.targetTouches[0].clientY)},!1),t.addEventListener("touchmove",function(n){1===n.targetTouches.length&&function(n){var o=n.targetTouches[0].clientY-e;0===t.scrollTop&&o>0&&n.preventDefault(),t.scrollHeight-t.scrollTop<=t.clientHeight&&o<0&&n.preventDefault()}(n)},!1)}();
</script>


<script>
document.addEventListener('DOMContentLoaded', function() {
    // Select all interactive elements
    var focusableElements = 'a[href], button, input, textarea, select, details, [tabindex]:not([tabindex="-1"])';
    var focusables = document.querySelectorAll(focusableElements);

    // Add a keydown event listener to each focusable element
    focusables.forEach(function(element) {
        element.addEventListener('keydown', function(e) {
            if (e.key === 'Tab') {
                // Prevent the default tab behavior
                e.preventDefault();
                var index = Array.prototype.indexOf.call(focusables, e.target);
                var nextElement = focusables[index + (e.shiftKey ? -1 : 1)];
                if (!nextElement) {
                    nextElement = focusables[e.shiftKey ? focusables.length - 1 : 0];
                }
                nextElement.focus();
            }
        });
    });
});
</script>

<script src="https://unpkg.com/infinite-scroll@4.0.1/dist/infinite-scroll.pkgd.min.js" defer=""></script>

<script>
// LOAD MORE
$(document).ready(function(){
  $('.list').infiniteScroll({
            path: '.w-pagination-next',
            append: '.item',
            button: '.w-pagination-next',
            history: false,
            scrollThreshold: false
        });
});
</script></body></html>